News Ledger Evidence preview
Back to ledger
IERTÉ NewsHealth

HSE agrees to fund Friedreich's Ataxia drug for patients

The HSE has approved the reimbursement of the drug Skyclarys for people with Friedreich's Ataxia.

Byline not supplied
Open original article
Ledger record
#2540
First seen
25 Aug 2026, 05:11 UTC
Last checked
27 Aug 2026, 04:30 UTC
Version history
5 versions
Current fingerprint
e1f6a789f9e1...88100e
01

Publisher layer

Recorded article metadata

Image URL supplied by RTÉ News.
Publisher
RTÉ News
Country
Ireland
Source published
25 Aug 2026, 05:00 UTC
Source updated
No update timestamp supplied
Byline
Not supplied
Section
Health
Source-supplied excerpt
The HSE has approved the reimbursement of the drug Skyclarys for people with Friedreich's Ataxia.
02

Change layer

Observed version timeline

  1. 5
    Revision observed

    HSE agrees to fund Friedreich's Ataxia drug for patients

    The HSE has approved the reimbursement of the drug Skyclarys for people with Friedreich's Ataxia.

    Changed fieldstitledescriptionTextcontentText
    Version SHA-256
    e1f6a789f9e1...88100e
    Capture SHA-256
    535e684d7ac0...636277
  2. 4
    Revision observed

    HSE approves Skyclarys reimbursement for FA patients

    The HSE has approved the reimbursement of the drug Skyclarys for people with Friedreich's ataxia.

    Changed fieldstitledescriptionTextcontentText
    Version SHA-256
    e885b51f9741...7a10f7
    Capture SHA-256
    dd6760140834...1c1918
  3. 3
    Revision observed

    HSE to consider new offer from drug firm over Skyclarys

    The prospect of a positive decision on the HSE providing the drug Skyclarys for people with Friedreich's ataxia has increased, with a new offer from the drug firm Biogen.

    Changed fieldsimageUrl
    Version SHA-256
    486d7b77a8f9...879e39
    Capture SHA-256
    b9f4ce0c946a...fe5764
  4. 2
    Revision observed

    HSE to consider new offer from drug firm over Skyclarys

    The prospect of a positive decision on the HSE providing the drug Skyclarys for people with Friedreich's ataxia has increased, with a new offer from the drug firm Biogen.

    Changed fieldstitledescriptionTextcontentText
    Version SHA-256
    cc5b67fc7562...4b30a2
    Capture SHA-256
    029e4f673ec5...64a9c3
  5. 1
    Initial capture

    Uncertainty over Skyclarys decision as HSE team to meet

    The HSE Senior Leadership Team will meet to discuss the drug Skyclarys, which is for people with the rare neurological condition, Friedreich's ataxia.

    Changed fieldstitlebylinedescriptionTextcontentTextsourcePublishedAtsourceUpdatedAtsectionimageUrltags
    Version SHA-256
    7e32da7ae381...39c10d
    Capture SHA-256
    5119836d2bc3...d9fff0
03

Interpretation layer

Labels with declared origins

Not an adjudication.

Publisher categories are copied from source metadata. Machine signals report observable wording or format and do not determine truth, intent, ethics, or wrongdoing.

  • machine content-type Reported news observable-rules-v1 / 70% rule confidence
  • publisher category Health rss-category
04

Public response layer

Reception snapshots

No reviewed reception capture yet.

Comment counts and samples remain absent until a lawful, source-specific capture method is reviewed. Absence is recorded instead of estimated.

05

Evidence layer

Capture provenance

Capture ID
#2395
Observed
25 Aug 2026, 13:42 UTC
HTTP result
200 / parsed
Raw payload
38,374 bytes, private gzip evidence
Collector
news-ledger/0.1
Public boundary
metadata and excerpt
Official source feedPublisher terms